BCL2 and breast cancer: Since prodigiosin and PU-H71 were reported to downregulate the level of BCL2 gene transcription in breast cancer cells41,42, and since TNBC is refractory to current treatment, to this end, we determined whether PU-H71, prodigiosin and their combination could inhibit BCL2 in MDA-MB-231 cell line.